85 Park Pl NE
Atlanta, GA 30303
United States
Georgia State University College of Law
biologics, pharmaceuticals, patents, statutory exclusivities, market exclusivity, data exclusivity, generics, biologics price competition, hatch, waxman, BPCIA, PPACA, FDA
public health, intellectual property, TRIPS, patent, healthcare, health, big data, innovation, health care, pharmaceuticals, alternatives, Hatch-Waxman, prizes, collectively governed systems, clinical trials, black box, transparency, Obamacare, privacy, human rights
biologics, pharmaceuticals, Price Competition and Innovation Act, FDA, data exclusivity, exclusivities, patents, Hatch-Waxman, BPCIA, primary patents, secondary patents, PTO, Food and Drug Administration, Patent and Trademark Office, market exclusivity, generic exclusivity
sperm, egg, semen, ova, ovum, insemination, IVF, ART, FDA, tissue, donation, gene, genetic disease, DNA, Public Health Service Act, PHSA, biologics, communicable disease, bioethics
Ownership fallacy, human organism, human being, patents, abortion, Thirteenth Amendment, patenting humans, OTA, Weldon Amendment, directed to or encompassing, chimera, cloning, humanzee, shemale, humouse, innovation, biomedicine, technology
gene patents, human genome, Myriad Genetics, patent claims, patent scope
COVID-19, coronavirus, necessity, lesser-evil, lesser harm, defense, privilege, intellectual property, IP, Lake Erie, Vincent v. Lake Erie, respirators, 3d printing, pharmaceuticals, public health, public necessity, private necessity, imminent harm, torts, common law, emergency
Alzheimer's, Food and Drug Administration, FDA, pharmaceuticals, drugs, regulation, administrative law, health, Chevron
healthcare, incentives, benefit corporations, pharmaceuticals, public health, healthcare reform, non-profit, for profit, hybrid corporations, non for profit, business entities, corporate form
COVID-19, coronavirus, SARS-CoV-2, pandemic, pharmaceuticals, vaccines, healthcare markets, incentives, for-profit, public health, innovation, remdesivir, Food and Drug Administration, FDA, Gilead, Ebola, SARS, MERS, preparedness, private public partnerships, PPPs, emergency response
Regulatory Competitive Shelters; regulatory exclusivity; data exclusivity; market exclusivity; generic exclusivity; Food and Drug Administration; Environmental Protection Agency; generic; follow-on; patents; innovation
Biologics, biopharmaceuticals, pharmaceuticals, Food and Drug Administration, FDA, pricing, competition, Biologics Price Competition and Innovation Act, BPCIA, BPCI Act, follow-on, access to medicine, generics, biosimilars, interchangeables, interchangeability, biosimilarity, automatic substitution
biologics, biosimilars, pharmaceuticals, follow-on, generics, innovation, biopharmaceuticals, competition, antitrust
Pharmaceuticals, biologics, exclusivity, patents, trade secrets, manufacturing information, data, access to medicine, Food and Drug Administration, FDA, biosimilars, interchangeable biosimilars, Biologics Price Competition and Innovation Act, BPCIA, BPCI Act, competition, innovation
FDA, Food and Drug Administration, COVID-19, hydroxychloroquine, convalescent COVID-19 plasma, vaccines, reactivity, administrative law
Genetics, DNA, Genomics, Genetic Privacy, Genetic Information, Genetic Property, Genetic Interests, Genetic Dimensions, Gene Therapy, Myriad Genetics, Moore v. Regents, Greenberg v. Miami, Maryland v. King, Genetic Identity, Genetic Objects, Gina, Genetic Discrimination, Genetic Testing, Sequencing
IP, patent, ISDS, investor-state arbitration, TRIPS, NAFTA, expropriation, fair and equitable treatment, utility, industrial application, promise doctrine, secondary patents, evergreening
Vaccines, COVID-19, Food and Drug Administration, FDA, Public Health, Vaccine Hesitancy, Emergency Use Authorization, EUA, chloroquine, hydroxychloroquine, convalescent plasma, coronavirus, pandemic, Office of Technology Assessment, OTA
pharmaceutical, biologic, biosimilar, patent, intellectual property, international intellectual property law, follow-on biologics, international trade agreements
assisted reproductive technology, sperm bank, tort liability, abortion politics, fraud
Regulatory competitive shelters, RCSs, Regulatory exclusivities, personalized medicine, patents, patentability, subject mater eligibility, FDA, innovation
Regulatory competitive shelters, RCS, regulatory exclusivities, agrobiotech, FIFRA, Generic Animal Drug and Patent Term Restoration Act, GADPTRA, genetically modified organisms, genetically modified animals, Federal Insecticide, Fungicide and Rodenticide Act, FDA, EPA, exclusivity
DNA, genetics, privacy, information, law
Bayh-Dole, Patents, Regulations, March-In, Pricing
